Skip to content
Bored Studies
RecruitingPhase 4

Two Dose Levels of Privigen in Pediatric CIDP

CSL Behring · NCT03684018

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 2–17 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
30
US sites recruiting
3
Study start
February 28, 2019
Record last updated
June 1, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment

Being studied: IgPro10

Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • - Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP.

Exclusion Criteria

  • - Absence of CIDP symptoms
  • -History or family history of inherited neuropathy
  • -Diagnosed developmental delay or regression
  • -History of thrombotic episode
  • -Known or suspected hypersensitivity to Privigen
  • -Known allergic or other severe reactions to blood products
  • -Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
  • -Pregnant or breastfeeding mother"

Recruiting US locations

  • Children's Hospital of Philadelphia

    Philadelphia, PA 19104

    Site contact: Use Central Contact

  • Neurology Rare Disease Center

    Flower Mound, TX 75028

    Site contact: Use Central Contact

  • Seattle Children's Hospital

    Seattle, WA 98105

    Site contact: Central Contact

Study contacts (from the official record)

  • Trial Registration Coordinator · 6108784697 · clinicaltrials@cslbehring.com
All neurology studies in Pennsylvania →
Two Dose Levels of Privigen in Pediatric CIDP (NCT03684018) | Bored Studies